Dwight H. Egan - 23 May 2026 Form 4 Insider Report for Co-Diagnostics, Inc. (CODX)

Reporting relationship: Chief Executive Officer, Director
Issuer ticker: CODX
Reported as of: 23 May 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 27 May 2026, 16:04:45 UTC
Prior SEC filing: 24 Nov 2025
Source filing: View source filing
Reporting owner signature: /s/ Dwight H. Egan

Key filing fact

Dwight H. Egan filed Form 4 for Co-Diagnostics, Inc. (CODX) on 27 May 2026.

Key facts

This page summarizes Dwight H. Egan's Form 4 filing for Co-Diagnostics, Inc. (CODX).
3 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 27 May 2026, 16:04.

Change

Previous filing in this sequence was filed on 24 Nov 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001712187 Primary reporting owner

Egan Dwight H

Relationship: Chief Executive Officer, Director
Address: 2401 S. FOOTHILL DRIVE SUITE D, SALT LAKE CITY
Signature: /s/ Dwight H. Egan
Signature date: 27 May 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

CODX transaction

Common Stock

Award

Transaction value
Shares: +4,584
Change %: +18%
Price: $0.000000^*
Shares after: 29,526
Date: 23 May 2026
Ownership: Direct
Footnotes: F1

CODX transaction

Common Stock

Disposed to Issuer

Transaction value
Shares: -1,633
Change %: -5.5%
Price: $5.07^*
Shares after: 27,893
Date: 23 May 2026
Ownership: Direct
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

CODX transaction Derivative

Restricted Stock Unit

Options Exercise

Transaction value
Shares: -4,584
Change %: -33%
Price: $0.000000^*
Shares after: 9,166
Date: 23 May 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 13,750
Exercise price: $0.000000
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Included in 9,167 restricted stock units awarded to the Reporting Person on May 15, 2023, pursuant to the Co-Diagnostics, Inc. 2015 Long Term Incentive Plan, and vest in 6 equal installments every 6 months commencing on November 23, 2023. Included in 9,167 restricted stock units awarded to the Reporting Person on April 26, 2024, pursuant to the Co-Diagnostics, Inc. 2015 Long Term Incentive Plan, and vest in 6 equal installments every 6 months commencing on November 23, 2024. Included in 9,167 restricted stock units awarded to the Reporting Person on August 13, 2025, pursuant to the Co-Diagnostics, Inc. 2015 Long Term Incentive Plan, and vest in 6 equal installments every 6 months commencing on November 23, 2025.

Footnote F2

Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSU's. This sale is mandated by the Issuer's election, under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.